thiazoles has been researched along with Cells, Neoplasm Circulating in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, M; Bokar, J; Brell, J; Chee, CE; Dowlati, A; Fu, P; Gibbons, J; Gudena, V; Krishnamurthi, S; Meropol, NJ; Nock, CJ; O'Brien, T; Reese, A; Saltzman, J; Teston, L; Wright, JJ | 1 |
| Aouba, A; Asnafi, V; Brouze, C; Canioni, D; Chandesris, MO; Dubreuil, P; Feger, F; Georgin-Lavialle, S; Gineste, P; Hanssens, K; Hermine, O; Lepelletier, Y; Letard, S; Lhermitte, L; Macintyre, E; Mansfield, CD; Moussy, A; Renand, A; Suarez, F; Yang, Y | 1 |
| Choe, JH; Choe, JM; Falchook, GS; Gallick, GE; George, GC; Hong, DS; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, S; Strauss, LC; Wheler, JJ | 1 |
2 trial(s) available for thiazoles and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Dasatinib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Dasatinib; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Interleukin-8; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neoplastic Cells, Circulating; Pyrimidines; Thiazoles; Young Adult | 2013 |
1 other study(ies) available for thiazoles and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Topics: Aged; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Chlorocebus aethiops; COS Cells; Female; Humans; Immunophenotyping; Leukemia, Mast-Cell; Mast Cells; Mutation; Neoplastic Cells, Circulating; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles; Tryptases | 2012 |